nusinersen
Selected indexed studies
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. (N Engl J Med, 2018) [PMID:29443664]
- Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study. (Muscle Nerve, 2021) [PMID:33501671]
- Nusinersen: A Treatment for Spinal Muscular Atrophy. (Ann Pharmacother, 2019) [PMID:30008228]
_Worker-drafted node — pending editorial review._
Connections
nusinersen is a side effect of
Sources
- An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies. (2024) pubmed
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. (2018) pubmed
- Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study. (2021) pubmed
- Nusinersen: A Treatment for Spinal Muscular Atrophy. (2019) pubmed
- Physical Therapy and Nusinersen Impact on Spinal Muscular Atrophy Rehabilitative Outcome. (2022) pubmed
- Nusinersen: First Global Approval. (2017) pubmed
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. (2016) pubmed
- Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy. (2020) pubmed
- Nusinersen treatment of spinal muscular atrophy - a systematic review. (2020) pubmed
- DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A Results. (2023) pubmed